I don't think LXRX will have to or be able to go it alone. Either a partner will show up, or the company will be bought out. Diabetes is a multi-billion dollar market and LXRX has a blockbuster drug that in one formulation does what no other company's drug does. I believe the present large decline we've seen, on low less than average volume, will end soon with LXRX back at 2.5 very soon, if not higher due to a buyout.
The recent price action is similar to what I've seen happen in other small biotechs just before major good news or a buyout is announced. We have a large percentage decline on less than average volume. Very suspicious and I've been buying heavily on the way down. Don't be surprised by a huge gap up in the near future.
I added to my holdings starting at 3.8 today and had another equal order in each nickel down, got filled all the way down to 3.65. This adds to my starter position from yesterday at 3.9
The history of ATRS is to miss by a penny or two, fall the day of earnings, then rebound completely within a couple weeks. This time will be no different. With it's recent approval, ATRS has never been in better shape fundamentally. Shorts will be looking to cover soon, but they won't get my shares below 4.
but my broker has no shares available to short. This #$%$ would be the ideal short -- more debt than cash and chronic quarterly losses. It was pumped up ahead of the forthcoming dilution to try to generate some bagholders, this is just a wonderful short both technically and fundamentally.